Fractyl raises series E funding of USD 55 million for diabetes cure

By Nikita Chaurasia  Date: 2020-08-10

Fractyl raises series E funding of USD 55 million for diabetes cure

Fractyl Laboratories raised series E funding of USD 55 million to continue financing the pivotal clinical trial of its potential non-surgical, non-drug treatment for Type 2 diabetes.

As per the trusted sources, the capital will be invested on mass-based startup’s Revita T2Di pivotal clinical trial of Revita DMR. Revita is observing the effect of Fractyl’s Revita DMR treatment on insulin requirements and glycemic control.

Reportedly, the funding round was led by the new investor named Taiwania Capital Management Corporation. The financing also involved the existing investors like Emergent Medical Partners, Bessemer Venture Partners, Domain Associates, True Ventures, General Catalyst, Mithril Capital Management, and GV. The funding round included first time commitments from CDIB Venture Capital Corp., Catalio Capital Management, and YJ Capital.

Michael Huang, managing partner at Taiwania Capital Management Corporation, has reportedly stated that type 2 diabetes and NAFLD/NASH have adverse effects on people’s health across the world and account for majority global healthcare expenditure. He further added that Fractyl has carried out studies which reveal Revita’s potential to enhance the outcomes of the treatment for type 2 diabetes.

Fractyl’s co-founder and CEO Harith Rajagopalan states that Fractyl’s mission is to treat diabetes type 2 in a better way by addressing its root cause, that can reverse the disease process rather than managing its symptoms. He said that they now have database of hundreds of patients who suffered from type 2 diabetes and have shown long term benefits of a single Revita treatment.

Rajagopalan added that he welcomes the new investors and the continued support of the returning investors who saw that they have the potential to redefine the treatment for metabolic diseases like NAFLD/NASH and type 2 diabetes.

The company is looking forward to beginning with their pivotal U.S. clinical trial later this year.

Source credits-

https://www.massdevice.com/fractyl-adds-55m-for-type-2-diabetes-pivotal-trial/

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

U.K. might ease lockdown restrictions following drop in COVID-19 cases

U.K. might ease lockdown restrictions following drop in COVID-19 cases

By Nikita Chaurasia

British Prime Minister Boris Johnson is reportedly planning to further ease lockdown restrictions in the United Kingdom. This announcement comes after Britain witnessed a drop in the daily death toll and case count, primarily due to rapid vaccination...

Maruti Suzuki India prolongs maintenance shutdown over COVID-19 fears

Maruti Suzuki India prolongs maintenance shutdown over COVID-19 fears

By Nikita Chaurasia

Maruti Suzuki India Limited has reportedly extended its maintenance shutdown from May 9th to May 16th amidst rising COVID-19 cases across the country. However, it is difficult to ascertain whether the intention behind the extended shutdown is to guar...

Amazon sets tougher rules for its delivery service partners’ employees

Amazon sets tougher rules for its delivery service partners’ employees

By Nikita Chaurasia

Amazon is known for closely managing its staff and contractors, and it also seeks to control the employees of the companies in which it works. Reportedly, the company has updated its policies for Amazon’s delivery partners wherein it lays out d...

BMW, Ford lead Solid Power’s USD 130 million Series B funding round

BMW, Ford lead Solid Power’s USD 130 million Series B funding round

By Nikita Chaurasia

Solid Power Inc., a leading U.S-based producer of solid-state batteries has reportedly secured USD 130 million in the Series B funding round led by renowned car makers namely Ford Motor Company and BMW Group.  These funds will be used to develo...

Pfizer donates COVID-19 treatment drugs worth USD 70 million to India

Pfizer donates COVID-19 treatment drugs worth USD 70 million to India

By Nikita Chaurasia

Reportedly, American multinational pharmaceutical firm Pfizer Inc. has extended a helping hand to India in the battle against Covid-19, sending drugs worth USD 70 million to the country. The company is also in discussion with the Indian government to...